Search Results for "Hypertension"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Hypertension. Results 141 to 150 of 401 total matches.
Iloprost (Aurlumyn) for Frostbite
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
hypertension.
STANDARD TREATMENT ― Frostbite occurs when freezing temperatures cause ice crystals to form ...
The FDA has approved Aurlumyn (Eicos Sciences),
an IV formulation of the prostacyclin analog iloprost,
to reduce the risk of digit amputation in adults
with severe frostbite. Iloprost is the first drug to be
approved by the FDA for treatment of severe frostbite;
it has been used off-label for this indication in the EU
and elsewhere for decades. In the US, iloprost is also
available as an inhaled formulation (Ventavis) for
treatment of pulmonary arterial hypertension.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):114 doi:10.58347/tml.2024.1707b | Show Introduction Hide Introduction
Everolimus and Pazopanib: Two New Drugs for Renal Cell Cancer
The Medical Letter on Drugs and Therapeutics • May 03, 2010 (Issue 1337)
have been diarrhea, hair color changes,
hypertension, nausea, fatigue, leukopenia, and AST,
ALT and bilirubin ...
Everolimus (Afinitor – Novartis) and pazopanib (Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib (Sutent) and sorafenib (Nexavar), two other oral multikinase inhibitors, and temsirolimus (Torisel), an IV multikinase inhibitor, were approved earlier for the same indication.
Two Drugs for Weight Loss
The Medical Letter on Drugs and Therapeutics • Sep 03, 2012 (Issue 1398)
)
and for patients who are overweight (BMI >27 kg/m2)
and have one weight-related risk factor such as
hypertension ...
In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai) is a selective serotonin 2C receptor agonist. Qsymia (Vivus) is a fixed-dose combination of the weight-loss drug phentermine and an extended-release (ER) formulation of topiramate. The new products are approved for use in obese patients (body mass index [BMI] of ≥30 kg/m2) and for patients who are overweight (BMI ≥27 kg/m2) and have one weight-related risk factor such as hypertension, dyslipidemia or...
Two New Oral Testosterone Products for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
(1944-2700 ng/dL) in 5% of patients.3
ADVERSE EFFECTS ― Hypertension (3%) was the only
adverse effect ...
The FDA has approved two new oral formulations
of testosterone undecanoate — Kyzatrex (Marius)
and Tlando (Antares) — for treatment of males
with a deficiency of endogenous testosterone
due to conditions such as Klinefelter syndrome,
orchiectomy, toxic damage from chemotherapy or
alcohol, or pituitary-hypothalamic injury caused
by tumors, trauma, or radiation. Jatenzo, another
oral testosterone undecanoate formulation, was
approved for the same indication in 2019. No
testosterone products are approved for treatment of
low testosterone levels due solely to...
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
reported in ≥5% of patients on dialysis included hypertension,
abdominal pain, dizziness, hypersensitivity ...
The FDA has approved daprodustat (Jesduvroq –
GSK), a hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 4 months. It is the first
HIF-PHI and the first oral drug to be approved in the
US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7 doi:10.58347/tml.2024.1696a | Show Introduction Hide Introduction
Drugs That Cause Sexual Dysfunction: An Update
The Medical Letter on Drugs and Therapeutics • Aug 07, 1992 (Issue 876)
and therapeutic efficacy in angina pectoris and hypertension. Drugs,
17:425, 1979
11. DW Hedley et al ...
Many commonly used drugs can interfere with sexual function in both men and women, causing loss of libido, interfering with erection or ejaculation in men, and delaying or preventing orgasm in women. Drug-related effects on sexual function may be difficult to distinguish from the effects of depression or disease, but most are reversible when drug use is stopped and sometimes when dosage is decreased. Since many patients are reluctant to talk about sexual difficulties, physicians may wish to ask about the possibility of drug-induced sexual dysfunction, particularly when they have...
Brimonidine - An Alpha2-Agonist for Glaucoma
The Medical Letter on Drugs and Therapeutics • Jun 06, 1997 (Issue 1002)
or ocular hypertension and for
its prevention in patients undergoing argon laser trabeculoplasty.
DOSAGE ...
Brimonidine tartrate 0.2% ophthalmic solution (Alphagan - Allergan), a selective alpha2-adrenergic agonist, has been approved by the US Food and Drug Administration (FDA) for treatment of increased intraocular pressure due to open-angle glaucoma or ocular hypertension and for its prevention in patients undergoing argon laser trabeculoplasty.
Quillivant XR - An Extended-Release Oral Suspension of Methylphenidate
The Medical Letter on Drugs and Therapeutics • Feb 04, 2013 (Issue 1409)
with symptomatic cardiovascular
disease, moderate to severe hypertension, hyperthyroidism,
glaucoma, or known ...
The FDA has approved a once-daily, extended-release
oral suspension of methylphenidate (Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity
disorder (ADHD). It is the first liquid formulation of the
drug to be marketed for once-daily use. A short-acting
oral solution (Methylin, and generics) has been available
since 2003.
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2013 (Issue 1418)
, macular edema, mild
hypertension, decreased pulmonary
function, serious viral infections
Teriflunomide ...
The FDA has approved dimethyl fumarate (Tecfidera –
Biogen Idec), formerly called BG-12, for treatment of
relapsing forms of multiple sclerosis (MS). It is the
third oral drug to be approved in recent years for this
indication.
An EUA for Sotrovimab for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
disease
Hypertension
COPD, moderate to severe asthma, or other chronic respiratory
disease ...
The investigational monoclonal antibody sotrovimab
(VIR-7831; GSK/Vir Biotechnology) has been granted
an FDA Emergency Use Authorization (EUA) for
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death.1 Two other monoclonal
antibody regimens are authorized for the same
indication: casirivimab (REGN10933) and imdevimab
(REGN10987) administered together, and bamlanivimab (LY-CoV555) and etesevimab (LYCoV016)
administered together.
The FDA revoked its EUA...